PatientSpotlight, by PanaceaIntelPatientSpotlight

Topic

GLP-1

Coverage of glp-1 across PatientSpotlight - the developments worth watching, the access reality, and what the next twelve months may bring. 2 pieces on this topic across therapy areas, newest first within each collection.

← All topics

Signals

1
SignalApr 26, 2026FDA · CMS · industry-filing

GLP-1 supply is normalising; access still depends on indication

Manufacturing capacity expansion has eased the chronic supply shortfall that defined 2023-24, but reimbursement variation by indication - obesity vs diabetes vs cardiovascular risk reduction - continues to define who can actually start therapy.

TreatmentGLP-1AccessRegulatory

Explained

1
ExplainedApr 26, 2026peer-reviewed · guideline-bodies · FDA

Why HFpEF is the chapter cardiology has been waiting to write

Heart failure with preserved ejection fraction was a diagnostic and therapeutic puzzle for thirty years. The arrival of SGLT2 inhibitors with HFpEF outcome benefit, combined with a more nuanced phenotype framework and the GLP-1 obesity-HFpEF subgroup data, has turned a disease without a treatment into a disease with a small but growing set of evidence-based options.

HfpefHeart failureSglt2GLP-1